SAN DIEGO, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Skye Bioscience, Inc. (NASDAQ: SKYE) securities between November 4, 2024 and October 3, 2025. Skye is a clinical stage biopharmaceutical company that focuses on developing molecules that modulate G protein-coupled receptors (“GPCRs”) to treat obesity, overweight, and metabolic diseases. The Company’s lead product candidate is nimacimab. Fo ...

Group 1 - Nxera Pharma has achieved a second significant R&D milestone in its collaboration with AbbVie, resulting in a payment of US$10 million [1][3] - The collaboration, initiated in 2022, focuses on discovering novel medicines targeting G protein-coupled receptors (GPCRs) related to neurological diseases [2][3] - Nxera is eligible for up to US$40 million in near-term research milestones and potential total milestones of up to US$1.2 billion, along with tiered royalties on global sales [3] Group 2 - Dr. Matt Barnes, Chief Scientific Officer of Nxera, emphasized the productivity of the collaboration and the progress made in developing novel molecules for neurological disease targets [4] - The milestone payment will be recognized in the third quarter of 2025 [4] - Nxera Pharma is a technology-driven biopharma company focused on developing specialty medicines for unmet medical needs in Japan and globally [6][7] Group 3 - Nxera has an extensive pipeline of over 30 active programs targeting major unmet needs in areas such as obesity, metabolic disorders, neurology, and immunology [7] - The company employs approximately 400 people across key locations including Tokyo, Osaka, London, Cambridge, Basel, and Seoul [8]